DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.40
+10.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.4M | — | — | 330.5M | 108.5M |
| Cost of Revenue | 5.8M | 11.2M | — | — | — |
| Gross Profit | (2.2M) | (11.2M) | — | 330.5M | 108.5M |
| Operating Expenses | |||||
| R&D Expense | 404.9M | 418.8M | 396.4M | 423.9M | 358.7M |
| SG&A Expense | 141.0M | 97.1M | 105.4M | 103.4M | 90.5M |
| General & Admin Expense | 36.3M | 97.1M | 105.4M | 103.4M | 90.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.7M | 28.3M | (14.5M) | — | — |
| Total Operating Expenses | 547.6M | 544.2M | 487.3M | 527.2M | 449.2M |
| Cost and Expenses | 408.9M | 555.3M | 487.3M | 527.2M | 449.2M |
| Operating Income (EBIT) | (532.0M) | (555.3M) | (487.3M) | (196.7M) | (340.7M) |
| Non-Operating | |||||
| Interest Income | 17.8M | 42.9M | 64.6M | 51.5M | 14.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 17.8M | 42.9M | 64.6M | 51.5M | 14.8M |
| Other Non-Op Income/Expense | 217.7M | 42.9M | 64.6M | 51.5M | 14.8M |
| Non-Operating Income (excl Interest) | (20.8M) | (42.9M) | 14.5M | (51.5M) | (14.8M) |
| EBT (Pre-Tax Income) | (314.3M) | (512.4M) | (422.7M) | (145.2M) | (326.0M) |
| Income Tax Expense | 102.0K | 102.0K | 68.0K | 30.0K | 21.0K |
| Bottom Line | |||||
| Net Income | (314.4M) | (512.5M) | (422.8M) | (145.2M) | (326.0M) |
| Earnings from Cont. Ops | (314.4M) | (512.5M) | (422.8M) | (145.2M) | (326.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (314.4M) | (512.5M) | (422.8M) | (145.2M) | (326.0M) |
| Per Share | |||||
| Basic EPS | ($1.73) | ($2.97) | ($2.57) | ($1.06) | ($2.60) |
| Diluted EPS | ($1.73) | ($2.97) | ($2.57) | ($1.06) | ($2.60) |
| Revenue Per Share | $0.11 | $0.00 | $0.00 | $2.41 | $0.86 |
| Shares | |||||
| Basic Shares Outstanding | 188.4M | 175.5M | 164.5M | 137.4M | 125.5M |
| Diluted Shares Outstanding | 192.1M | 175.5M | 164.5M | 137.4M | 125.5M |
| Profitability Metrics | |||||
| EBITDA | (501.9M) | (497.6M) | (492.9M) | (128.5M) | (315.6M) |
| D&A | 9.3M | 14.8M | 9.0M | 16.7M | 10.4M |
| EBIT | (384.4M) | (512.4M) | (501.9M) | (145.2M) | (326.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026